TNFSF11 and neoplasm: In contrast, recent clinical studies have demonstrated that denosumab treatment reduced the relative content of the neoplastic stromal cells in patients with GCT [12], and another immunohistochemical study using tissue specimens from patients with GCTB indicated that the overexpression of RANKL by tumor stromal cells may be responsible for the osteolytic behavior of these cells in GCTBs [4].